N/A
Completed N=179
FIRAZYR General Drug Use-Results Survey (Japan)
Hereditary Angioedema (HAE)
Source: ClinicalTrials.gov NCT04057131 ↗
Enrolled (actual)
179
Serious AEs
0.7%
Results posted
Feb 2025
Primary outcomePrimary: Number of Participants With Adverse Events — 22 Participants
Summary
The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events |
22 | — |
| PRIMARY Number of Participants With Adverse Drug Reaction |
19 | — |
| PRIMARY Time to Treatment for Attack |
120.0 | — |
| PRIMARY Time to First Symptom Relief |
60.0 | — |
| PRIMARY Time to Complete Resolution of Attack |
780.0 | — |
| PRIMARY Total Duration of Attack |
1425.0 | — |
Eligibility Criteria
Inclusion Criteria
- Hereditary angioedema (HAE) participants in Japan who receive FIRAZYR for first time in the real world clinical setting.
Exclusion Criteria
Data sourced from ClinicalTrials.gov (NCT04057131). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.